Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Adamson Analytical Laboratories, Inc.
WARNING LETTER
•Adamson Analytical Laboratories, Inc.•March 23, 2021

Adamson Analytical Laboratories, Inc. – FDA Warning Letter, Mar 23, 2021

Record Details

The FDA inspected Adamson Analytical Laboratories, Inc. from March 8-23, 2021, identifying significant Current Good Manufacturing Practice (CGMP) violations for finished pharmaceuticals, rendering their drugs adulterated. The firm, a contract testing laboratory for prescription and over-the-counter drug products and APIs, received an inadequate response to their Form FDA 483.

Key violations include: 1. **Inadequate Computer System Controls (21 CFR 211.68(b)):** Laboratory personnel had administrative privileges on Gas Chromatography (GC) data acquisition systems, allowing data deletion/alteration. High-Performance Liquid Chromatography (HPLC) and GC instruments operated without activated audit trails from April 2018 to February 2021. Electronic microbial challenge efficacy testing worksheets used unvalidated formulas, generating erroneous data. This is a repeat violation from a 2016 warning letter. 2. **Failure to Establish Laboratory Control Mechanisms (21 CFR 211.160(a)):** Critical changes to electronic laboratory monitoring, such as implementing electronic worksheets and activating instrument software audit trails, occurred without Quality Unit (QU) oversight or proper change control.

The FDA recommends retaining a qualified consultant for data integrity remediation and CGMP compliance, emphasizing that the firm's executive management remains responsible. The firm must provide a comprehensive investigation into data inaccuracies, a risk assessment, and a management strategy with a global

Company
Adamson Analytical Laboratories, Inc.
Inspection date
March 23, 2021
Product type
Drugs
Office
Division of Pharmaceutical Quality Operations IV
Person
  • Steven E. Porter (Program Division Director)
View Company Profile

ID · d9a8da45-c585-45ee-be56-26366467e36b

Violation Codes6
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.68(b)21 CFR 211.2221 CFR 211.160(a)

Full citation text and observation details available on the Dashboard.

Other documents for Adamson Analytical Laboratories, Inc.
  • 483 - 2024-09-12September 12, 2024
  • 483 - 2022-10-04October 4, 2022
  • 483 - 2021-03-23March 23, 2021
  • 483 - 2017-02-10February 10, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Adamson Analytical Laboratories, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.